Trials / Completed
CompletedNCT02835105
A Study of Ascending Single Doses of Surotomycin in Healthy Participants (MK-4261-008)
A Randomized, Double-Blinded, Placebo-Controlled, Single-Dose, Safety and Pharmacokinetic Study of Ascending Doses of CB-183,315 in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This study aims to assess the safety, tolerability, and pharmacokinetics (PK) of a single oral dose of surotomycin (CB-183,315) at ascending dose levels when given to healthy males and females.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Surotomycin | A single oral dose of either 0.5, 1, 2 or 4 g surotomycin in hard gelatin capsules |
| DRUG | Placebo | A single oral dose of placebo for surotomycin in hard gelatin capsules |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2009-03-01
- Completion
- 2009-03-01
- First posted
- 2016-07-15
- Last updated
- 2016-07-22
Source: ClinicalTrials.gov record NCT02835105. Inclusion in this directory is not an endorsement.